Related references
Note: Only part of the references are listed.Mechanism-based concepts of size and maturity in pharmacokinetics
B. J. Anderson et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2008)
Emerging evidence of the impact of kidney disease on drug metabolism and transport
T. D. Nolin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation
Y. Le Meur et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
Gene-specific effects of inflammatory Cytokines on cytochrome P4502C, 2B6 and 3A4 mRNA levels in human Hepatocytes
Alison E. Aitken et al.
DRUG METABOLISM AND DISPOSITION (2007)
The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide
Maarten Naesens et al.
TRANSPLANTATION (2007)
The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers
E. Levesque et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients
Christine E. Staatz et al.
CLINICAL PHARMACOKINETICS (2007)
Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure
Jose Michaud et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: A population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients
Reinier M. van Hest et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
EM Ginzler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGTIA9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients
DRJ Kuypers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450
J Michaud et al.
BRITISH JOURNAL OF PHARMACOLOGY (2005)
Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients
I Neumann et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2003)
Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins
G Weber et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2002)
Determination of mycophenolic acid and its phenol glucuronide metabolite in human plasma and urine by high-performance liquid chromatography
K Wiwattanawongsa et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2001)
Current issues in therapeutic drug monitoring of mycophenolic acid: Report of a roundtable discussion
LM Shaw et al.
THERAPEUTIC DRUG MONITORING (2001)
The safety and efficacy of MMF in lupus nephritis: a pilot study
EJ Kingdon et al.
LUPUS (2001)
Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
TM Chan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation
LM Shaw et al.
THERAPEUTIC DRUG MONITORING (2000)
Share Paper
